Pertuzumab: A review of its use for first-line combination treatment of her2-positive metastatic breast cancer

Drugs

Volumn 73, Issue 13, 2013, Pages 1491-1502

  McCormack, Paul L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PERTUZUMAB; PLACEBO; TRASTUZUMAB;

ADD ON THERAPY; APPETITE; ARTICLE; ASTHENIA; BREAST CANCER; BREAST METASTASIS; CANCER THERAPY; CARDIOTOXICITY; CELL PROLIFERATION; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DRY SKIN; FATIGUE; FEBRILE NEUTROPENIA; GRANULOCYTOPENIA; HUMAN; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LEUKOPENIA; LOADING DRUG DOSE; NAUSEA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; SIDE EFFECT; TUMOR CELL;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASM PROTEINS; RECEPTOR, ERBB-2; TAXOIDS;

EID: 84884655057     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0109-0     Document Type: Article

References (52)

1. Ross JS, Slodkowska EA, Symmans WF, et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009;14(4):320-68.
2. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131(1):18-43.
3. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-82.
4. Hudis CA. Trastuzumab: mechanism of action and use in clinical practice. N Engl J Med. 2007;357(1):39-51.
5. Gennari R, Menard S, Fagnoni F, et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res. 2004;10(17):5650-5.
6. European Medicines Agency. Herceptin (trastuzumab): summary of product characteristics. 2010. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/000278/WC500074922.pdf. Accessed 8 Aug 2013.
7. Genentech Inc. Herceptin (trastuzumab): US prescribing information. 2010. http://www.gene.com/download/pdf/herceptin-prescribing.pdf. Accessed 8 Aug 2013.
8. Gradishar WJ. HER2 therapy: an abundance of riches. N Engl J Med. 2012;366(2):176-8.
9. European Medicines Agency. Perjeta (pertuzumab): summary of product characteristics. 2013. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/002547/WC500140980.pdf. Accessed 8 Aug 2013.
10. US FDA. Perjeta (pertuzumab): US prescribing information. 2012. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/125409lbl.pdf. Accessed 8 Aug 2013.
11. Franklin MC, Carey KD, Vajdos FF, et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell. 2004;5(4):317-28.
12. Agus DB, Akita RW, Fox WD, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2002;2(2):127-37.
13. Scheuer W, Friess T, Burtscher H, et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009;69(24):9330-6.
14. Adams CW, Allison DE, Flagella K, et al. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother. 2006;55(6):717-27.
15. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127-37.
16. Burgess AW, Cho HS, Eigenbrot C, et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell. 2003;12(3):541-52.
17. Lee-Hoeflich ST, Crocker L, Yao E, et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 2008;68(14):5878-87.
18. Bossenmaier B, Hasmann M, Koll H, et al. Presence of HER2/HER3 heterodimers predicts antitumor effects of pertuzumab (Omnitarg) in different human xenograft models [abstract no. 5342]. Proc Am Assoc Cancer Res. 2004;45:1232.
19. Friess T, Bauer S, Burger AM, et al. In vivo activity of recombinant humanized monoclonal antibody 2C4 in xenografts is independent of tumor type and degree of HER2 overexpression [abstract no. 496]. Eur J Cancer. 2002;38(Suppl. 7):S149.
20. Malik MA, Totpal K, Balter I, et al. Dose-response studies of recombinant humanized monoclonal antibody 2C4 in tumor xenograft models [abstract no. 773]. Proc Am Assoc Cancer Res. 2003;44(2nd ed):150.
21. Nahta R, Hung M-C, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 2004;64(7):2343-6.
22. Fuentes G, Scaltriti M, Baselga J, et al. Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism. Breast Cancer Res. 2011;13(3):R54.
23. Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol. 2010;28(7):1138-44.
24. Cortes J, Baselga J, Fumoleau P, et al. Pertuzumab and trastuzumab: exploratory biomarker correlations with clinical benefit in patients with metastatic HER2-positive breast cancer [abstract no. 1066]. J Clin Oncol. 2010;28(15 Suppl. 1).
25. Cortes J, Fumoleau P, Bianchi GV, et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012;30(14):1594-600.
26. Garg A, Li J, Clark E, et al. Exposure-response (E-R) analysis of pertuzumab (PTZ) in patients with HER2-positive (HER2+) metastatic breast cancer (MBC): effect on QTc prolongation and other ECG parameters [abstract no. PI-78]. Clin Pharmacol Ther. 2013;93(Suppl. 1):S42.
27. Attard G, Kitzen J, Blagden SP, et al. A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours. Br J Cancer. 2007;97(10):1338-43.
28. Yamamoto N, Yamada Y, Fujiwara Y, et al. Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (pertuzumab, RO4368451) in Japanese patients with solid tumors. Jpn J Clin Oncol. 2009;39(4):260-6.
29. Agus DB, Gordon MS, Taylor C, et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol. 2005;23(11):2534-43.
30. Gianni L, Lladó A, Bianchi G, et al. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010;28(7):1131-7.
31. Cortes J, Swain S, Kudaba I, et al. Pharmacokinetics (Pk) of pertuzumab (P) with trastuzumab (T) and docetaxel (D) in HER2-positive first-line metastatic breast cancer (MBC): results from the phase III trial CLEOPATRA [abstract no. 344P]. 37th Congress of the European Society for Medical Oncology, 28 Sep-2 Oct 2012, Vienna.
32. Ng CM, Lum BL, Gimenez V, et al. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis. Pharm Res. 2006;23(6):1275-84.
33. Baselga J, Cortés J, Kim S-B, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109-19.
34. US FDA. Center for Drug Evaluation and Research medical review of pertuzumab. 2012. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2012/ 125409Orig1s000MedR.pdf. Accessed 8 Aug 2013.
35. Swain SM, Kim SB, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14(6):461-71.
36. Cortes J, Baselga J, Im YH, et al. Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. Ann Oncol. 2013. doi: 10.1093/annonc/mdt274.
37. Swain SM, Ewer MS, Cortés J, et al. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. Oncologist. 2013;18:257-64.
38. Baselga J, Cortes J, Im S-A, et al. Adverse events with pertuzumab and trastuzumab: evolution during treatment with and without docetaxel in CLEOPATRA [abstract no. 597]. J Clin Oncol. 2012;30(15 Suppl. 1).
39. Cardoso F, Harbeck N, Fallowfield L, et al. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl. 7):vii11-9.
40. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer (version 2.2013). 2013. http://www.nccn.org/ professionals/physician-gls/pdf/breast.pdf. Accessed 15 Jul 2013.
41. Miles D, Peretz-Yablonski T, Ciruelos E, et al. Pertuzumab in combination with trastuzumab and a taxane for the first-line treatment of patients with HER2-positive advanced breast cancer: a single arm phase IIIb study (PERUSE) [abstract no. 409TiP]. 37th Congress of the European Society for Medical Oncology, 27 Sep-1 Oct 2012, Vienna.
42. ClinicalTrials.gov (pertuzumab AND breast cancer). 2013. http://clinicaltrials.gov/ct2/results/displayOpt?flds=a&flds=b&flds= f&flds=g&flds=k&flds=l&flds=r&flds=o&submit-fld-opt= on&term=pertuzumab+AND+breast&show-flds=Y. Accessed 8 Aug 2013.
43. Gianni L, Pienkowski T, Im Y-H, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25-32.
44. Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013. doi: 10.1093/annonc/mdt182.
45. Ellis PA, Barrios CH, Im Y, et al. MARIANNE: a phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC) [abstract no. TPS102]. J Clin Oncol. 2011;29(15 Suppl. 1).
46. Hoffman-La Roche. A study of trastuzumab emtansine (T-DM1) plus pertuzumab/pertuzumab placebo versus trastuzumab [Herceptin] plus a taxane in patients with metastatic breast cancer (MARIANNE) [ClinicalTrials.gov identifier NCT01120184]. US National Institutes of Health, ClincialTrials.gov [online]. 2013. http://clinicaltrials.gov/ct2/show/NCT01120184?term=NCT01120184&rank= 1. Accessed 8 Aug 2013.
47. von Minckwitz G, Baselga J, Bradbury I, et al. Adjuvant Pertuzumab and Herceptin IN IniTial therapY of breast cancer: APHINITY [abstract no. OT1-02-04]. Cancer Res. 2011;71(24 Suppl. 3):602S.
48. Hoffman-La Roche. A study of pertuzumab in addition to chemotherapy and Herceptin (trastuzumab) as adjuvant therapy in patients with HER2-positive primary breast cancer. [ClinicalTrials.gov identifier NCT01358877]. US National Institutes of Health, ClincialTrials.gov [online]. 2013. http://clinicaltrials. gov/ct2/show/NCT01358877?term=NCT01358877&rank=1. Accessed 8 Aug 2013.
49. Hoffman-La Roche. A study of pertuzumab in combination with trastuzumab plus an aromatase inhibitor in patients with hormone receptor-positive, metastatic HER2-positive breast cancer. [ClinicalTrials.gov identifier NCT01491737]. US National Institutes of Health, ClincialTrials.gov [online]. 2013. http://clinicaltrials.gov/ct2/show/NCT01491737?term=NCT01491737&rank= 1. Accessed 8 Aug 2013.
50. Hoffman-La Roche. A study of pertuzumab in combination with Herceptin (trastuzumab) and vinorelbine in first line in patients with metastatic or locally advanced HER2-positive breast cancer. 2013. http://clinicaltrials.gov/ ct2/show/NCT01565083?term=pertuzumab+AND+breast&rank=16&submit-fld-opt=. Accessed 8 Aug 2013.
51. Andersson M, Lopez-Vega JM, Del Mastro L, et al. Pertuzumab and trastuzumab in combination with vinorelbine for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer (LABC/MBC): a single-arm, two-cohort, phase II study (VELVET) [abstract no. 408TiP]. Ann Oncol. 2012;23(Suppl. 9):ix142.
52. Genentech. An observational study of pregnancy and pregnancy outcomes in women with breast cancer treated with Herceptin or Perjeta in combination with Herceptin during pregnancy or within 6 months prior to conception (MotHER). [ClinicalTrials.gov identifier NCT00833963]. US National Institutes of Health, ClincialTrials.gov [online]. 2012. http://clinicaltrials.gov/ct2/show/ NCT00833963?term=NCT00833963&rank=1. Accessed 8 Aug 2013.